MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it will provide a complete review of the Qnexa development program to investors and analysts on Thursday, December 6, 2007, in New York.
